Aligos Therapeutics’ (ALGS) Sell (D-) Rating Reiterated at Weiss Ratings

Weiss Ratings restated their sell (d-) rating on shares of Aligos Therapeutics (NASDAQ:ALGS) in a research report report published on Friday,Weiss Ratings reports.

Separately, HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Aligos Therapeutics in a report on Friday, September 12th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $50.00.

Aligos Therapeutics Stock Performance

NASDAQ ALGS opened at $9.69 on Friday. Aligos Therapeutics has a one year low of $3.76 and a one year high of $46.80. The company has a market capitalization of $59.59 million, a price-to-earnings ratio of -0.49 and a beta of 2.77. The company’s 50-day simple moving average is $10.11 and its two-hundred day simple moving average is $7.95.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.35) by $0.82. The firm had revenue of $0.97 million for the quarter, compared to the consensus estimate of $0.43 million. Aligos Therapeutics had a negative net margin of 2,337.24% and a negative return on equity of 22.41%. Equities analysts expect that Aligos Therapeutics will post -10.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aligos Therapeutics

A number of large investors have recently made changes to their positions in ALGS. Sio Capital Management LLC lifted its holdings in shares of Aligos Therapeutics by 85.9% during the 2nd quarter. Sio Capital Management LLC now owns 335,937 shares of the company’s stock valued at $2,422,000 after purchasing an additional 155,217 shares during the last quarter. XTX Topco Ltd purchased a new position in Aligos Therapeutics during the 2nd quarter worth $100,000. Geode Capital Management LLC increased its position in Aligos Therapeutics by 21.3% during the 2nd quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock valued at $246,000 after buying an additional 5,978 shares in the last quarter. Woodline Partners LP acquired a new position in Aligos Therapeutics during the 1st quarter valued at about $2,602,000. Finally, Alyeska Investment Group L.P. purchased a new stake in Aligos Therapeutics in the first quarter valued at about $3,399,000. 60.43% of the stock is owned by institutional investors and hedge funds.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).